ZURICH, Oct 7 (Reuters) - Novartis AG's NVA237 had promising results in a mid-stage trial in patients with a progressive lung disease, the Swiss drugmaker said on Tuesday. NVA237, which was licensed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback